Rationale for diphosphonate therapy in hypercalcemia of malignancy
- 23 February 1987
- journal article
- editorial
- Published by Elsevier in The American Journal of Medicine
- Vol. 82 (2) , 1-5
- https://doi.org/10.1016/0002-9343(87)90482-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-I-transformed lymphocytes.Journal of Clinical Investigation, 1986
- Frequency and partial characterization of adenylate cyclase-stimulating activity in tumors associated with humoral hypercalcemia of malignancyJournal of Bone and Mineral Research, 1986
- Purification of Peptides with Parathyroid Hormone-Like Bioactivity from Human and Rat Malignancies Associated with Hypercalcemia*Endocrinology, 1986
- Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells.Journal of Clinical Investigation, 1986
- PATHOGENESIS OF HYPERCALCAEMIA OF MALIGNANCYClinical Endocrinology, 1985
- Mechanism of malignant hypercalcaemia in carcinoma of the breast.BMJ, 1985
- Tumor products and the hypercalcemia of malignancy.Journal of Clinical Investigation, 1985
- The pathobiology of the osteoclast.Journal of Clinical Pathology, 1985
- Hypercalcemia in malignant disease without evidence of bone destructionThe American Journal of Medicine, 1956